이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

정서적 고통을 겪는 성인을 위한 PST 훈련 음성 지원 인공지능 상담사(SPEAC) 연구(2단계) (SPEAC)

2026년 8월 26일 업데이트: Jun Ma, University of Illinois Chicago

Approximately 200 Participants with mild-to-moderate, untreated depression and/or anxiety will be randomly assigned (by chance, like flipping a coin) to 1 of 3 study groups: Lumen Coached Problem-Solving Treatment (PST) (n=100), Human Coached PST (n=50), and optional (delayed) Lumen Coached PST as waitlist control (n=50) to improve emotional health. All participants will complete assessments at baseline and at 18 weeks post randomization.

Depending on the group assignment the PST program will be delivered by Lumen, a virtual voice-based coach on a study iPad, or by a human coach in person for the first session and then via videoconference or phone for the remaining 7 sessions. Participants assigned to the waitlist control group can receive the Lumen coached PST on a study iPad after completing their 18-week follow-up assessment.

Participants will receive 8 coaching sessions to learn problem-solving skills and work on unresolved problems in daily living that may be interfering with their emotional well-being and contributing to depression and anxiety symptoms.

연구 개요

상세 설명

All participants will complete measurements of neural target engagement and treatment outcomes at both baseline (0 week) and 18 weeks.

Study Visit 1: This will include (1) Physical measurements such as height, weight, and blood pressure, (2) functional magnetic resonance imaging (fMRI) scan, (3) surveys of intervention-related measures, and (4) surveys of patient-reported outcomes, such as depressive and anxiety symptoms, social functioning, and health-related quality of life.

Following the successful completion of Visit 1 and all the surveys, participants will be randomly assigned (by chance, like flipping a coin) to 1 of 3 study groups, as described below.

Problem Solving Treatment (PST) Groups

Group 1: Lumen Coached Group :

Participants assigned to this group will attend an Intervention Orientation session to receive the Coach Lumen tutorial, a study iPad, and a Lumen Intervention Workbook. They will complete 8 PST sessions (4 weekly and then 4 biweekly) with Coach Lumen at home over 12 weeks.

Group 2: Human Coached Group Participants assigned to this group will receive a study iPad and Human-Coached Intervention Workbook, and will complete 8 PST sessions (4 weekly and then 4 biweekly) with a trained health coach over 12 weeks. They will complete the first session in person and then the remaining sessions via videoconference or phone.

Group 3: Optional (Delayed) Lumen Coached Group Participants assigned to this group may choose to attend a Lumen Orientation session to receive training and a study iPad to complete 8 PST sessions with Coach Lumen after completing their follow-up assessment at 18 weeks.

Regardless of the group assignment, participants will complete brief Nightly Mood Check-in surveys about their thoughts, feelings, and experiences over the day, for 7 nights, approximately every other week over 18 weeks (i.e., a total of 58 nights). These check-ins are sent via text message to their mobile phone.

Study Visit 2:

Regardless of group assignment, participants will be asked to attend a second in-person visit for data collection at 18 weeks. Like Visit 1, Visit 2 will include physical measurements, a brain scan (after a negative pregnancy urine test, if applicable), and online surveys (if not yet completed before the visit), and will last approximately 90 minutes.

연구 유형

중재적

등록 (실제)

200

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Illinois
      • Chicago, Illinois, 미국, 60608
        • Department of Medicine, Vitoux Program on Aging and Prevention
      • Chicago, Illinois, 미국, 60612
        • UIMC Advanced Imaging Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age: ≥ 18 years
  • Emotional distress defined by elevated depressive (PHQ-9 scores 10-19) and/or anxious symptoms (GAD-7 scores 10-14)
  • Willing and able to provide informed eConsent and HIPAA authorization

Exclusion Criteria:

  • Unable to speak, read, or understand English for informed consent
  • Current pharmacotherapy or psychotherapy (individual or professionally led group therapy) for depression or anxiety (note: participants are not withdrawn post-randomization if they begin pharmacotherapy drugs or start psychotherapy during the study.)
  • Suicidal ideation per PHQ-9 with active plan
  • Bipolar or psychotic disorder, or current psychiatric treatment
  • Weight ≥325 pounds due to brain scanner constraints, MRI contraindications, traumatic brain injuries, and tumor or any other known structural abnormality in the brain
  • Severe medical condition (e.g., myocardial infarction or stroke or new cancer diagnosis in the past 6 months, end-stage organ failure, terminal illness) or residence in a long-term care facility
  • Diagnosis of cancer (other than non-melanoma skin cancer) that is/was active or treated with radiation or chemotherapy within the past year
  • Active alcohol or substance use disorder (including prescription drugs) based on the CAGE Questionnaire Adapted to Include Drugs (CAGE-AID)
  • Cognitive impairment based on the Callahan 6-item screener
  • Current or planned pregnancy or lactating (<6 months postpartum)
  • Participation in other investigational treatment studies that would significantly affect participation in this study, raise safety concerns, and/or confound outcomes (participant may be asked to provide the informed consent of the other study for final decision on exclusion by a study psychiatrist)
  • Family/household member of an already enrolled participant or of a study team member
  • Plan to move out of the Chicago area during the study period
  • Does not have reliable Wi-Fi Internet at home
  • Unwillingness to user personal mobile device to receive study text messages
  • Investigator discretion for clinical safety or protocol adherence reasons

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Group 1: Lumen Coached Group

Participants in this group will attend an Intervention Orientation session to receive the Coach Lumen tutorial, a study iPad, and a Lumen Intervention Workbook. They will complete 8 PST sessions with Coach Lumen using their study assigned iPad at home over 12 weeks. The first 4 sessions occur weekly and then the last 4 occur every other week. Participants will receive automated reminders on the day before and on the day of their scheduled session, and have the opportunity to reschedule sessions through the iPad. Participants will work with Coach Lumen to learn problem-solving skills to address current life challenges, plan activities, and complete home activities. Participants will also complete surveys before and after each PST session: a mood assessment survey before and a user experience survey after. At the end of study, Participants may be invited to provide their perspective regarding their Lumen use experience.

Lumen Intervention Orientation. Participants in the Lumen intervention arm attend a Lumen orientation visit (60 minutes) during which they will be given a Lumen intervention tutorial and receive a study iPad, configured to limit access to only the Lumen intervention enabled on the device. Before leaving, participants are scheduled for the first PST session with Coach Lumen. At the end of each PST session, participants are prompted to schedule their next session with Coach Lumen. They receive automated reminder notifications 1 day prior to their next session, on the session day, and have the opportunity to make up missed sessions. As needed, Lumen intervention orientations can be done remotely.

활성 비교기: Group 2: Human Coached Group

Participants in this group will receive a study iPad and Human-Coached Intervention Workbook and will complete the first of 8 PST sessions in person with a trained health coach. Participants' first PST session will be in person for approximately 1 hour. Participants will complete the remaining sessions remotely via Zoom (or by phone, if necessary) using their study iPad. The first 4 sessions occur weekly and then the last 4 occur every other week. Participants will receive automated reminder notifications on the day before and on the day of their scheduled session, and have the opportunity to reschedule sessions with their coach. Participants will also complete a mood assessment survey at the beginning of each PST session. Participants will work with their health coach to learn problem-solving skills to address current life challenges, plan activities, and complete home activities.

Participants in the human coached PST arm will serve as active treatment controls given the demonstrated efficacy of human coached PST in depression and anxiety. They will complete 8 PST sessions with a human coach; first session in-person and remaining sessions via videoconferencing (i.e., Zoom preferred; with phone calls allowed) on the same 4 weekly and then 4 biweekly schedule as that for Lumen participants. Participants will receive a study iPad to use for their PST sessions via zoom. Participants also complete the PHQ-9 and GAD-7 during each session. Participants will receive a certificate of completion.

위약 비교기: Group 3: Optional (Delayed) Lumen Coached Group

Participants assigned to this group can choose to attend a Lumen Orientation session to receive training and a study iPad to complete 8 PST sessions with Coach Lumen after their follow-up assessment at 18 weeks. They will receive 8 Sunday mood assessment surveys to complete (4 every Sunday and then 4 every other Sunday).

Waitlist control participants will only complete assessments during the 18-week trial period. At the end of their 18-week assessment, they will have the option to complete 8 PST sessions on their assigned iPads.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline Functional Magnetic Resonance Scan at 18 Weeks
기간: Baseline, 18 weeks

Two neural targets defined a priori, specifically activation of the amygdala for nonconscious threat-related emotional reactivity and activation of the dorsal lateral prefrontal cortex (DLPFC) for cognitive control will be assessed using fMRI. The right DLPFC is the primary neural target, while the left DLPFC and bilateral amygdala are secondary neural targets. In the facial emotion viewing paradigm, facial expression stimuli are standardized black and white photographs of 8 identities (4 female, 4 male) with evoked expressions of threat-related emotions (fear, anger), loss-related emotions (sadness) and reward-related emotions (happiness), along with neutral. For the Go-NoGo paradigm, the 'Go' and 'NoGo' stimuli are presented for 500 ms each with an inter-stimulus interval of 750 ms. The beta weight is a standardized regression coefficient. Positive beta weights mean greater activation, and Negative beta weights mean less activation in the specific brain region being monitored.

Baseline, 18 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline Hospital Anxiety and Depression Scale (HADS) at 18 Weeks
기간: Baseline, 18 weeks

HADS, including 7 questions for anxiety and 7 questions for depression, measures self-reported anxiety and depression in a general medical population of patients. Each item on the questionnaire is scored from 0-3 and the score for either anxiety or depression ranges between 0 and 21 with the following categories: normal 0-7, mild 8-10, moderate 11-14, and severe 15-21. Total score for the entire scale (psychological distress) ranges from 0 to 42, with higher score indicating more distress.

Baseline, 18 weeks
Change From Baseline Penn State Worry Questionnaire (PSWQ) at 18 Weeks
기간: Baseline, 18 weeks

Penn State Worry Questionnaire (PSWQ) is a self-reported, 16-item, Likert-type scale that measures the trait of worry. Each item is related on a 1-5 scale. The total score of the scale ranges from 16 to 80, with higher scores indicating higher trait worry.

Baseline, 18 weeks
Change From Baseline Positive and Negative Affect Schedule (PANAS) at 18 Weeks
기간: Baseline, 18 weeks

Positive and Negative Affect Schedule (PANAS) consists of two 10-item self-reported scales to measure positive and negative affect. Each item asks about the extent one has felt a positive or negative feeling on a 5-point scale of 1 (not at all) to 5 (very much). Positive Affect scores can range from 10 - 50, with higher scores representing higher levels of positive affect. Negative affect scores can range from 10 - 50, with lower scores representing lower levels of negative affect.

Baseline, 18 weeks
Change From Baseline Social Problem-Solving Inventory-Revised: Short Form (SPSI-R:S) at 18 Weeks
기간: Baseline, 18 weeks

Participants' problem solving abilities will be assessed using the Social Problem-Solving Inventory-Revised: Short Form (SPSI-R:S) that contains 25 items in the following 5 subscales: positive problem orientation (PPO), negative problem orientation (NPO), rational problem solving (RPS), impulsive/careless style (ICS), and avoidance style (AS). Each item is rated on a 5-point scale ranging from "not at all true of me" (0) to "extremely true of me" (4). The total problem-solving ability score=(PPO raw score/5)+(20- NPO raw score)/5+ (RPS raw score/5)+(20- ICS raw score)/5+(20- AS raw score)/5. It ranged from 0 to 20, with the higher score indicating more productive problem-solving skills. Subscales scores (PPO, NPO, RPS, ICS, and AS) are raw scores without reversal. They range from 0 to 20, with the higher scores indicating the more positive and negative orientation, and the more rational, impulsive/careless, and avoidance style, respectively.

Baseline, 18 weeks
Change From Baseline Dysfunctional Attitudes Scale (DAS) at 18 Weeks
기간: Baseline, 18 weeks

Dysfunctional Attitudes Scale (DAS Form A) is a 40-item self-reported scale that measures the presence and intensity of dysfunctional attitudes. Each item is rated a 7-point Likert scale (7 = fully agree; 1 = fully disagree) for a total scale range of 40 to 280. The higher the sum of the 40-items, the more dysfunctional attitudes an individual possesses.

Baseline, 18 weeks
Change From Baseline Sheehan Disability Total Score at 18 Weeks
기간: Baseline, 18 weeks

The Sheehan Disability Scale is a validated questionnaire that measures functional disability and is sensitive to treatment effects in clinical trials. Patients rate the extent to which their symptoms impair work/school, social, and family life on a visual analog scale from 0 to 10. Total score is the sum of the three separate scores on work/school, social, and family life. Total scores range 0-30, with higher scores indicating greater functional impairment.

Baseline, 18 weeks
Change From Baseline Work Productivity and Activity Impairment Questionnaire (WPAI) at 18 Weeks
기간: Baseline, 18 weeks

The Work Productivity and Activity Impairment questionnaire (WPAI) consists of 6 questions: 1 = currently employed; 2 = hours missed due to health problems; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree health affected productivity while working (using a 0 to 10 Visual Analogue Scale (VAS)); 6 = degree health affected productivity in regular unpaid activities (VAS). The recall period for the questions 2 to 6 is 7 days. Four main outcomes can be generated from the WPAI-GH and expressed in percentages by multiplying the following scores by 100: 1) percent work time missed due to health = Q2/(Q2 + Q4) for those who were currently employed; 2) percent impairment while working due to health = Q5/10 for those who were currently employed and actually worked in the past 7 days; 3) percent overall work impairment due to health Q2/(Q2 + Q4) + ((1 - Q2/(Q2 + Q4)) × (Q5/10)) for those who were currently employed; 4) percent activity impairment due to health Q6/10 for all.

Baseline, 18 weeks
Change From Baseline Daily Mood (Positive Affect and Negative Affect) at 18 Weeks
기간: Baseline and every 2 weeks (i.e., on weeks 2, 4, 6, 8, 10, 12, and 18)

Daily end-of-day assessments will be captured over a one-week period at baseline and every 2 weeks (i.e., on weeks 2, 4, 6, 8, 10, 12, and 18). Changes in weekly average from baseline to week 18 are reported below. During active treatment in the Lumen arm and the in-person PST arm, this will occur for 3 days prior to, the day of, and for 3 days after a scheduled PST session. For waitlist controls, this will occur for 7 days starting on Sunday of each assigned week. Daily mood will be measured using 8 mood items (0 = Not at all, 6 = Extremely), with 4 measuring positive affect and 4 measuring negative affect. Positive affect score is mean of item scores, with higher scores indicating more positive affect. Negative affect score is mean of item scores, with higher scores indicating more negative affect.

Baseline and every 2 weeks (i.e., on weeks 2, 4, 6, 8, 10, 12, and 18)
Change From Baseline Daily Stress at 18 Weeks
기간: Baseline and every 2 weeks (i.e., on weeks 2, 4, 6, 8, 10, 12, and 18)

Daily end-of-day assessments will be captured over a one-week period at baseline and every 2 weeks (i.e., on weeks 2, 4, 6, 8, 10, 12, and 18). Changes in weekly average from baseline to week 18 are reported below. During active treatment in the Lumen arm and the in-person PST arm, this will occur for 3 days prior to, the day of, and for 3 days after a scheduled PST session. For waitlist controls, this will occur for 7 days starting on Sunday of each assigned week. Daily stress will be assessed by the question "how stressful was your day today" (0 = Not at all, 6 = Extremely).

Baseline and every 2 weeks (i.e., on weeks 2, 4, 6, 8, 10, 12, and 18)
Change From Baseline Daily Appraisal at 18 Weeks
기간: Baseline and every 2 weeks (i.e., on weeks 2, 4, 6, 8, 10, 12, and 18)

Daily end-of-day assessments will be captured over a one-week period at baseline and every 2 weeks (i.e., on weeks 2, 4, 6, 8, 10, 12, and 18). Changes in weekly average from baseline to week 18 are reported below. During active treatment in the Lumen arm and the in-person PST arm, this will occur for 3 days prior to, the day of, and for 3 days after a scheduled PST session. For waitlist controls, this will occur for 7 days starting on Sunday of each assigned week. The appraisal question asks "To what degree were you able to accept your problem as normal or an expected part of everyday life?" (0 = Not at all, 6 = A great deal), which a higher score indicating a greater degree of ability to accept problem as normal or expected.

Baseline and every 2 weeks (i.e., on weeks 2, 4, 6, 8, 10, 12, and 18)

기타 결과 측정

결과 측정
측정값 설명
기간
Patient Health Questionnaire (PHQ-9)
기간: Weeks 1, 2, 3, 4, 6, 8, 10, 12

PHQ-9 is a self-administered instrument for screening, diagnosing, monitoring, and measuring the severity of depression. It rates the frequency of symptoms as "0" (not at all) to "3" (nearly every day) and has been validated for use in primary care. The PHQ-9 total score ranges from 0 to 27 and is categorized as follows: None or minimal depression 0-4, Mild depression 5-9, Moderate depression 10-14, Moderately severe depression 15-19, and Severe depression 20-27. PHQ-9 will be administered before each PST session (in weeks 1, 2, 3, 4, 6, 8, 10, 12) in Luman and Human groups, and at the same schedule in the Waitlist group. Changes in PHQ-9 scores from session 1 to session 8 are reported below.

Weeks 1, 2, 3, 4, 6, 8, 10, 12
Generalized Anxiety Disorder Scale (GAD-7)
기간: Weeks 1, 2, 3, 4, 6, 8, 10, 12

GAD-7 is a valid and reliable 7-question self-report measure assessing the severity of generalized anxiety symptoms over the past two weeks. Total scores range from 0 to 21, with higher scores indicating a greater degree of anxiety symptom severity. GAD-7 will be administered before each PST session (in weeks 1, 2, 3, 4, 6, 8, 10, 12) in Luman and Human groups, and at the same schedule in the Waitlist group. Changes in GAD-7 scores from session 1 to session 8 are reported below.

Weeks 1, 2, 3, 4, 6, 8, 10, 12
User Experience Questionnaire-Short Version (UEQ-S)
기간: After Lumen Session 1, Session 4, Session 8

User Experience Questionnaire-Short version (UEQ-S) is a validated instrument containing 8 items from the 26 items of the original UEQ. UEQ-S measures user experience. From the UEQ-S survey, scale values were calculated by rescaling the survey responses to the range -3 to 3 and UEQ-S total score were calculated as mean of survey responses. UEQ-S total scores <-0.8 represented a negative evaluation, between -0.8 and 0.8 represented a neutral evaluation, and >0.8 represent a positive evaluation.

After Lumen Session 1, Session 4, Session 8
Change in Adapted Working Alliance Inventory for Digital Coaching Interventions (WAI-Tech) From First PST Session in Week 1 to Eighth Session in 12 Weeks
기간: After Lumen Session 1, Session 4, Session 8

Adapted Working Alliance Inventory for digital coaching interventions (WAI-Tech) was based closely on the original 36-item WAI and uses a parallel set of 36 items rated on a 7-point scale (1 = "never" to 7 = "always") to measure the level of alliance between patient and digital coach along 3 domains: Task (12 items), Bond (12 items), and Goal (12 items). An overall score was calculated based on item means. A higher overall score reflected a greater treatment alliance.

After Lumen Session 1, Session 4, Session 8

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Jun Ma, MD, PhD, University of Illinois Chicago

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 1월 23일

기본 완료 (실제)

2025년 4월 15일

연구 완료 (실제)

2025년 4월 15일

연구 등록 날짜

최초 제출

2022년 10월 28일

QC 기준을 충족하는 최초 제출

2022년 10월 28일

처음 게시됨 (실제)

2022년 11월 3일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 23일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 26일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2022-1052
  • R33MH119237 (미국 NIH 보조금/계약)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다